Skip to main content
. 2011 Oct 27;286(51):43871–43880. doi: 10.1074/jbc.M111.297515

FIGURE 2.

FIGURE 2.

Treatment with D-JNKI1 inhibits phosphorylation of c-Jun and APP. A, representative Western blots and relative quantifications show that increasing doses of D-JNKI1 inhibit phosphorylation of c-Jun by 35 and 50%, respectively. 22 mg/kg of D-JNKI1 inhibits phosphorylation of APP by 50%. Data are expressed as mean ± S.E. (one-way ANOVA). **, p < 0.01; ***, p < 0.001 versus vehicle (veh) (n = 6); Dunnett's post hoc test. B, chronic treatment with D-JNKI1 in TgCRND8 leads to a 56 and 50% decrease in phosphorylation of c-Jun in the cortex and hippocampus, respectively. Data are expressed as mean ± S.E. **, p < 0.01; ***, p < 0.001 (Tg vehicle (n = 8) versus Tg D-JNKI1 (n = 8); Student's t test). C, Western blots and relative quantifications showing that chronic treatment with D-JNKI1 in TgCRND8 leads to a 62 and 65% decrease in phosphorylation of c-Jun in the liver and pancreas, respectively. Data are expressed as mean ± S.E. *, p < 0.05; **, p < 0.01 (Tg vehicle (n = 8) versus Tg D-JNKI1 (n = 8); Student's t test).